Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 8, Number 6, June 2016, pages 449-460

Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson’s Disease Patients: A Meta-Analysis of Randomized Controlled Trials

Figures

Figure 1.
Figure 1. Flow diagram of study selection for meta-analysis.
Figure 2.
Figure 2. Forest plot of meta-analysis of randomized controlled trials of non-ergot dopamine agonists and the risk of newly diagnosed heart failure in Parkinson’s disease patients.
Figure 3.
Figure 3. Forest plot of meta-analysis of randomized controlled trials of non-ergot dopamine agonists and the risk of mortality in Parkinson’s disease patients.
Figure 4.
Figure 4. Forest plot of meta-analysis of randomized controlled trials of non-ergot dopamine agonists and the risk of any cardiovascular events in Parkinson’s disease patients.
Figure 5.
Figure 5. Forest plot of meta-analysis of randomized controlled trials of non-ergot dopamine agonists and the risk of heart failure in Parkinson’s disease patients: stratified by individual drugs.
Figure 6.
Figure 6. Forest plot of meta-analysis of randomized controlled trials of non-ergot dopamine agonists and the risk of heart failure in Parkinson’s disease patients: stratified by Parkinson’s disease stage.
Figure 7.
Figure 7. Forest plot of meta-analysis of randomized controlled trials of non-ergot dopamine agonists and the risk of heart failure in Parkinson’s disease patients: stratified by length of follow-up (< 24 weeks: short term; ≥ 24 weeks: long term).

Table

Table 1. Use of Non-Ergot Dopamine Agonists Versus Placebo and the Risk of Incident Heart Failure in Parkinson’s Disease Patients
 
RR (95% CI)
Main analysis
  Random effects0.925 (0.297 - 2.879)
Stratified analysis
  Individual drugs
    Rotigotine (n = 2)1.022 (0.180 - 5.79)
    Pardoprunox (n = 1)1.71 (0.081 - 36.001)
    Pramipexole (n = 2)1.249 (0.155 - 10.088)
    Ropinirole (n =1)0.190 (0.009 - 4.079)
  Stage of Parkinson’s disease
    Advanced stage (n = 3)0.889 (0.182 - 4.346)
    Early stage (n = 2)1.312 (0.171 - 10.059)
    Both, early and advanced (n = 1)0.560 (0.038 - 8.325)
  Length of follow-up
    < 24 weeks (n = 3)0.925 (0.177 - 4.825)
    ≥ 24 weeks (n = 3)0.925 (0.194 - 4.415)